association radio et chimiotherapie cancer

ASSOCIATION RADIO ET CHIMIOTHERAPIE
CANCER BRONCHIQUE NON A PETITES CELLULES
Protocole
Schéma
thérapeutique
Espacement
intercure
Protocoles détaillés Type de
chimio Référentiel Réf. Biblio.
CARBOPLATINE
+
DOCETAXEL
Carboplatine
AUC2 J1
Docétaxel
20mg/m² J1
7 jours
RT-CT : CARBOPLATINE (AUC2) + DOCETAXEL
(20) (RTNPC13)
RT-CT concomitante AMM ou standard Das & coll. [3]
CARBOPLATINE
+
ETOPOSIDE
RT-CT : CARBOPLATINE (AUC5) + ETOPOSIDE
(100) (RTNPC02)
CARBOPLATINE
+
ETOPOSIDE
PHOSPHATE
RT-CT : CARBOPLATINE (AUC5) + ETOPOPHOS
(100) (RTNPC01)
Choy & coll. [1]
Belani & coll. [2]
CISPLATINE
+
DOCETAXEL
Cisplatine
20mg/m² J1
Docétaxel
20mg/m² J1
7 jours
RT-CT : CISPLATINE (20) + DOCETAXEL (20)
HEBDO (RTNPC14)
RT-CT concomitante AMM ou standard
Tokuda & coll. [4]
Aydiner & coll. [5]
Senan & coll. [6]
RT-CT : CISPLATINE (80) HC + ETOPOSIDE (100)
(RTNPC06)
RT-CT : CISPLATINE (80) HJ + ETOPOSIDE (100)
(RTNPC08)
RT-CT : CISPLATINE (2x40) HJ Frac J1J2 +
ETOPOSIDE (100) (RTNPC04)
RT-CT : CISPLATINE (80) HC + ETOPOPHOS
(100) (RTNPC05)
RT-CT : CISPLATINE (80) HJ + ETOPOPHOS
(100) (RTNPC07)
RT-CT : CISPLATINE (2x40) HJ Frac J1J2 +
ETOPOPHOS (100) (RTNPC03)
Carboplatine
AUC5 J1
Etoposide / Etoposide
Phosphate
100mg/m² J1, J2 et J3
21 jours
RT-CT concomitante
AMM ou standard
Cisplatine
100mg/m² J1
Etoposide / Etoposide
Phosphate
100mg/m² J1, J2 et J3
21 jours
RT-CT concomitante
AMM ou standard
CISPLATINE
+
ETOPOSIDE
CISPLATINE
+
ETOPOSIDE
PHOSPHATE
CARBOPLATINE
+
PACLITAXEL
Carboplatine
AUC2 J1
Paclitaxel
45mg/m² J1
7 jours
RT-CT : CARBOPLATINE (AUC2) + PACLITAXEL
(45) HEBDO (RTNPC12)
RT-CT concomitante
AMM ou standard
THESAURUS REGIONAL BOURGOGNE : THORAX RTCT NPC
Dernière mise à jour : mars 2014
1

ASSOCIATION RADIO ET CHIMIOTHERAPIE
CANCER BRONCHIQUE NON A PETITES CELLULES
Protocole
Schéma
thérapeutique
Espacement
intercure
Protocoles détaillés Type de
chimio Référentiel Réf. Biblio.
RT-CT : CISPLATINE (2x40) HJ Frac J1J2 +
VINORELBINE (15) (RTNPC09)
RT-CT : CISPLATINE (80) HC + VINORELBINE
(15) (RTNPC10)
RT-CT : CISPLATINE (80) HJ + VINORELBINE
(15) (RTNPC11)
[6] Senan & coll. A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with
unresectable locally advanced non-small-cell lung cancer. Annals of Oncology
Références bibliographiques:
[1] Choy & coll. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 10:3316-3322 (1998)
[2] Belani & coll. Combined chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non-Small-Cell Lung Cancer : A Randomized Phase II Locally Advanced Multi-Modality Protocol. J
Clin Oncol 25:5883-5891 (2005)
[3] Das & coll. Results from a single institution phase II trial of concurrent docetaxel/carboplatin/radiotherapy followed by surgical resection and consolidation docetaxel/carboplatin in stage III non-small-cell
lung cancer. Clin Lung Cancer 12(5):280-5 (2011)
[4] Tokuda & coll. Long-term follow-up of phase II trial of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer. Acta Oncol 51(4):537-40 (2012)
[5] Aydiner & coll. Induction chemotherapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer : a phase II study. Clin
Lung Cancer 12(5):286-92 (2011)
CISPLATINE
+
VINORELBINE
Cisplatine
80mg/m² J1
Vinorelbine inj.
15mg/m² J1 et J8
21 jours
RT-CT concomitante
AMM ou standard
THESAURUS REGIONAL BOURGOGNE : THORAX RTCT NPC
Dernière mise à jour : mars 2014
2